LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]
AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.
Related Stories
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 7 wks
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 3 months
Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer / 7 days
Engineered bacteria show promise as tumor‑targeting therapy in preclinical studies / 6 wks
Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 6 wks
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 3 months
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try FDA, Vitamin D, Obesity, Health Disparities and look for the RSS link.
StackHealth Time Machine